Tyrogenex Inc. to Present at BIO National Venture Conference 2009

WEST PALM BEACH, Fla.--(Business Wire)--
Tyrogenex Inc., a company focused on an oral, multi-kinase angiogenesis
inhibitor, is pleased to announce that Sheridan G. Snyder, President and Chief
Executive Officer, will present at BIO National Venture Conference on Tuesday,
March 31, 2009 at 2:20 PM in Boston, Massachusetts.

Mr. Snyder will provide an overview of Tyrogenex and its lead candidate, X-82,
an oral, VEGFR/PDGFR inhibitor currently in development for solid tumors.

About Tyrogenex Inc.

Tyrogenex Inc. is a biotechnology company, headquartered in West Palm Beach,
Florida, USA, focused on the research and development of its multi-kinase
angiogenesis inhibitor for the treatment of solid tumors. Tyrogenex`s lead
candidate, X-82, is finalizing preclinical studies and preparing to enter Phase
I clinical trials. For more information about Tyrogenex, please visit
www.tyrogenex.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements include, but
are not limited to, statements about future expectations, plan and future
development of Tyrogenex Inc.`s products and technologies. These forward-looking
statements about future expectations, plans and prospects of the development of
Tyrogenex Inc.`s products and technologies involve significant risks,
uncertainties and assumptions, including the risk that the development of our
multi-kinase inhibitor may be delayed or may not proceed as planned and we may
not be able to complete development of any multi-kinase-based product, the risk
that the FDA approval process may be delayed for any drugs that we develop,
risks related to development and commercialization of products by our
competitors, risks related to our ability to control the timing and terms of
collaborations with third parties and the possibility that other companies or
organizations may assert patent rights that prevent us from developing our
products. Actual results may differ materially from those Tyrogenex Inc.
contemplated by these forward-looking statements. Tyrogenex Inc. does not
undertake to update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date of this
release.

Tyrogenex, Inc., West Palm Beach
Kimberly Harrow, 561/835-9356
kharrow@biocatalystintl.com

Copyright Business Wire 2009